Akebia Therapeutics, Inc. (AKBA)
| Market Cap | 233.60M |
| Revenue (ttm) | 193.61M |
| Net Income (ttm) | -61.09M |
| Shares Out | 188.39M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,126,420 |
| Open | 1.30 |
| Previous Close | 1.28 |
| Day's Range | 1.22 - 1.31 |
| 52-Week Range | 0.49 - 1.84 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 4.33 (+249.19%) |
| Earnings Date | Nov 8, 2023 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels ... [Read more]
Financial Performance
In 2022, AKBA's revenue was $292.48 million, an increase of 38.19% compared to the previous year's $211.65 million. Losses were -$94.23 million, -66.59% less than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price forecast is $4.33, which is an increase of 249.19% from the latest price.
News
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Dec. 1, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, grante...
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Akebia to host conference call at 8:00 a.m. ET Vadadustat NDA assigned a PDUFA date of March 27, 2024 Vadadustat approved in 36 countries, including Australia and Taiwan Akebia strengthens cash positi...
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
Company Strengthens Cash Position in Advance of Potential Vadadustat Launch CAMBRIDGE, Mass. , Nov. 2, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company wit...
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on November 8 th at 8:00 a.m. ET CAMBRIDGE, Mass.
Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
March 27, 2024 Set as User Fee Goal Date CAMBRIDGE, Mass. , Oct. 25, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives...
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
CAMBRIDGE, Mass. , Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
CAMBRIDGE, Mass. , Sept. 28, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
CAMBRIDGE, Mass. , Sept. 26, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that Australia's Therapeutic Goods Administration (TGA) has granted approval for Vafseo® (...
Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass. , Sept. 6, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 Reports Auryxia® ...
Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
Akebia Received Type A Meeting Minutes from the FDA CAMBRIDGE, Mass. , Aug. 24, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better...
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023
Akebia Receives Notification of Deficiency from Nasdaq Regarding Late Form 10-Q Filing CAMBRIDGE, Mass. , Aug. 17, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical co...
Akebia Therapeutics Provides Update on Form 10-Q Filing
Akebia announces late filing of its second quarter earnings and Form 10-Q Akebia reaffirms 2023 net product revenue guidance of $175 - $180 million Akebia believes its cash resources as of June 30, 20...
Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
CAMBRIDGE, Mass. , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today...
Akebia Announces Swissmedic Approval of Vafseo® (vadadustat)
CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authoriza...
Akebia Therapeutics Announces New Chief Financial Officer
CAMBRIDGE, Mass. , June 13, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today...
Akebia Therapeutics to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today a...
FDA Provides Akebia Therapeutics a Path Forward for Vadadustat
FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies Akebia plans to request Type A meeting and then resubmit NDA Akebia...
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia
Medice brings extensive expertise in nephrology and an established European dialysis business Akebia to receive a $10 million upfront payment, potential for up to $100 million in commercial milestone ...
Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass. , May 22, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today ...